CN104114165A - 用于治疗憩室病的方法和组合物 - Google Patents
用于治疗憩室病的方法和组合物 Download PDFInfo
- Publication number
- CN104114165A CN104114165A CN201280062802.4A CN201280062802A CN104114165A CN 104114165 A CN104114165 A CN 104114165A CN 201280062802 A CN201280062802 A CN 201280062802A CN 104114165 A CN104114165 A CN 104114165A
- Authority
- CN
- China
- Prior art keywords
- glutaminate
- diverticulosis
- compositions
- salt
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 206010013554 Diverticulum Diseases 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 23
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 36
- 230000037396 body weight Effects 0.000 claims abstract description 12
- 239000000835 fiber Substances 0.000 claims description 18
- 241001597008 Nomeidae Species 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000003203 everyday effect Effects 0.000 claims description 5
- 239000013589 supplement Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 235000003421 Plantago ovata Nutrition 0.000 claims description 3
- 239000009223 Psyllium Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229940070687 psyllium Drugs 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 241001499741 Plantago arenaria Species 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 11
- 150000008540 L-glutamines Chemical class 0.000 abstract 2
- 229930182816 L-glutamine Natural products 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- -1 benzathine salt Chemical class 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 6
- 238000002052 colonoscopy Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000021071 low fiber diet Nutrition 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001499733 Plantago asiatica Species 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229940029830 benefiber Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940081970 citrucel Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229940042003 metamucil Drugs 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical class C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/24—Cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及用于治疗憩室病的方法和组合物。更具体地，本发明涉及包括L-谷氨酰胺、其盐或其衍生物的组合物及这种组合物在治疗憩室病中的用途。在方法方面，本发明提供一种治疗憩室病的方法。所述方法包括患有憩室病的人每天摄入0.05g/kg体重至10.0g/kg体重的谷氨酰胺、L-谷氨酰胺盐或L-谷氨酰胺衍生物。
Description
本申请要求2011年12月19日提交的美国临时专利申请号61/630,831的优先权权益。将该申请的全部内容以其整体引入本文作为参考。
发明领域
本发明涉及用于治疗憩室病的方法和组合物。更具体地，本发明涉及包括L-谷氨酰胺、其盐或其衍生物的组合物及这种组合物在治疗憩室病中的用途。
发明背景
憩室病指其中沿着结肠壁形成小囊袋(即，憩室)的病症。该小囊袋通常直径为5至10毫米，并且在约50％的60岁以上人中形成。
憩室病的病因学仍没有完全了解。目前的理论集中于观察到的种群(cultures)之间的营养差异：进食高纤维饮食的那些种群(例如亚洲人和非洲人)具有非常低的憩室病发病率；进食低纤维饮食的那些种群(例如美国人和欧洲人)具有高的憩室病发病率。某些医生相信进食低纤维饮食的人的结肠使废物移动通过他的结肠必须比平常人施加更高压力。该相对高压使结肠的脆弱点变形，其中血管穿过肠壁的肌肉层，从而形成小囊袋。
许多憩室病的病例没有被发现，因为该病症单独不会引起症状。憩室病通常在患者经历并发症比如疼痛的憩室性疾病或憩室炎之后才被诊断出。在其它病例中，其是在过筛检查(例如结肠镜检查)期间被发现。
通常使用营养指导方案和药物的组合治疗憩室病。患者可以遵照下述饮食方案：包括摄入高纤维食品，目标为每天消耗30至35克的纤维。解痉药可以被开处方以松驰消化道周围的肌肉。当发生憩室炎或憩室病的其它并发症时，可以给药止痛药。
本领域需要可用于治疗憩室病的另外的组合物和方法。这是本发明的一个目的。
附图说明
图1显示L-谷氨酰胺(1)和L-谷氨酰胺盐和衍生物(2)。
发明内容
本发明涉及用于治疗憩室病的方法和组合物。更具体地，本发明涉及包括L-谷氨酰胺、其盐或其衍生物的组合物及这样的组合物在治疗憩室病中的用途。
在方法方面，本发明提供一种治疗憩室病的方法。所述方法包括由患有憩室病的人每天摄入0.05g/kg体重至10.0g/kg体重的L-谷氨酰胺、L-谷氨酰胺盐或L-谷氨酰胺衍生物。
在组合物方面，本发明提供一种用于治疗憩室病的组合物。所述组合物包括L-谷氨酰胺、L-谷氨酰胺盐或L-谷氨酰胺衍生物和纤维补充剂。
具体实施方式
本发明涉及用于治疗憩室病的方法和组合物。更具体地，本发明涉及包括L-谷氨酰胺、其盐或其衍生物的组合物及这种组合物在治疗憩室病中的用途。
L-谷氨酰胺的结构显示在图1中，化合物1。L-谷氨酰胺盐和衍生物显示为图1中的化合物2。关于化合物2，非限制性L-谷氨酰胺盐和衍生物具有下述取代基：
R1为NH2；
R2为NH2、NH3 +、NH3Br、NH3OPO3H、NH3OC(O)CH3(即，乙酸盐)、NH3OC(O)CHCHCO2H(即，富马酸盐-反式烯烃)、NH3OC(O)CH(OH)CH(OH)CO2H(即，酒石酸盐)、NH3OC(O)CHCHCO2H(即，马来酸盐-顺式烯烃)、NH3OC(O)CH2-C(OH)(CO2H)CH2CO2H(即，柠檬酸盐)、NH3OC(O)CO2H(即，草酸盐)、NH3OS(O)2OH(即，甲磺酸盐)、NH3OS(O)2C6H4CH3(即，对-甲苯磺酸盐)和NH3OC(O)C(O)CH2CH2CO2H(即，α-酮戊二酸盐)。
R3为OH、O-、ONa、OK、OCa、OLi、ONH2(CH2C6H5)CH2CH2NHCH2C6H6(即，苄星盐(benzathine salt))、ON(CH2CH3)2CH2CH2OC(O)C6H3ClNH2(即，氯普鲁卡因盐)、ON(CH3)3CH2CH2OH(即，胆碱盐)、ONH2(CH2CH2OH)2(即，二乙醇胺盐)、ONH3CH2CH2OH(即，乙醇胺盐)、ONH3CH2CH2NH2(即，乙二胺盐)、ONH2(CH3)CH2CH(OH)CH(OH)CH(OH)CH(OH)CH2OH(即，葡甲胺盐)、ONH3C(CH2OH)3(即，氨基丁三醇盐)、ONH3C(CH3)3(即，叔-丁胺盐)、ON(CH2CH3)2CH2CH2OC(O)C6H4NH2(即，普鲁卡因盐)、NHCH(CH3)CO2H、NHCH(CH(CH3)2)CO2H、NHCH(CH(CH3)(CH2CH3))CO2H、NHCH(CH2CH(CH3)2)CO2H、NHCH(CH2CH2SCH3)CO2H、NHCH(CH2C6H5)CO2H、NHCH(CH2C6H5OH)CO2H、NHCH(CH2C8H6N)CO2H、NHCH2CO2H、NHCH(CH2CH2C(O)NH2)CO2H、NHCH(CH2C(O)NH2)CO2H、NHCH(CH(OH)CH3)CO2H、NHCH(CH2OH)CO2H、NHCH(CH2CH2CO2H)CO2H、NHCH(CH2CO2H)CO2H。
通常，向寻找憩室病治疗的人给药单一化合物(例如，L-谷氨酰胺)。然而，在某些情况下，可以给药两种或多种化合物的混合物。例如，可以给药L-谷氨酰胺与一种或多种L-谷氨酰胺盐或衍生物。
L-谷氨酰胺、其盐、衍生物或混合物可以以任何合适的方法给药。例如，在某些情况下，其以水溶液形式给药。所述溶液可以仅含有呈溶解的成分的L-谷氨酰胺、盐或衍生物，或者其可以包括其它可药用化合物。这种化合物的非限制性实例包括缓冲剂和调味剂。
其中可以给药L-谷氨酰胺、其盐、衍生物或混合物的方式的其它非限制性实例包括：呈在液体(例如，水或汁)中的悬浮液；呈固体，粉末或另外的形式(例如，丸剂或胶囊剂)；呈与食品的混合物(例如，酸乳酪)。如同水溶液一样，前述给药形式可以包括其它可药用的成分。
根据本发明给药的L-谷氨酰胺、盐或衍生物的用量通常为0.05g/kg体重至10.0g/kg体重。常常，用量范围为0.10g/kg体重至8.0g/kg体重。在某些情况下，用量范围为0.15g/kg体重到7.0g/kg体重。
通常向人每天一次给药L-谷氨酰胺、其盐或衍生物。然而，当指定时，可以每天给药所述化合物多于一次。
当使用本发明的组合物治疗憩室病时，它们可以与用于治疗憩室病的其它方法结合。例如，所述组合物可以作为集中于包含提高纤维的饮食方案的一部分给药。
本发明的组合物也可以给药和/或与纤维补充剂比如CITRUCEL、BENEFIBER和METAMUCIL组合给药。纤维补充剂可以包括可溶性和/或不溶性纤维，或者补充剂可以完全由可溶性和/或不溶性纤维组成。所述组合物可以与其组合的纤维的非限制性实例包括：甲基纤维素；小麦糊精天然可溶性纤维；和欧车前纤维(psyllium fiber)。纤维也可以包括前述类型纤维的组合。
所述组合物和纤维的组合可以是任何合适的形式。所述组合可以是例如粉剂、胶囊剂(capsule)、囊片剂(caplet)、咀嚼片的形式。其也可以包括其它补充形式，比如饮料或凝胶剂。
根据本发明的组合物可用于治疗憩室病，如通过对结肠小囊袋成像的许多不同方法测定的。成像方法的非限制性实例包括：结肠镜检查；计算机断层扫描；和基于钡灌肠的x-射线。
在给药L-谷氨酰胺、其盐或衍生物三个月、四个月、五个月、六个月、七个月、八个月、九个月、十个月、十一个月或十二个月之后，观察到患者结肠中的小囊袋数量减少至少百分之二十五(25)。在某些病例下，小囊袋的数量已经减少至少百分之五十(50)或百分之七十五(75)。在其它病例下，小囊袋的数量已经减少至少百分之八十(80)、百分之八十五(85)、百分之九十(90)或百分之九十五(95)。
试验结果
当通过结肠镜检查观察时，一个人具有许多憩室。该人每天摄入呈水溶液形式的30g L-谷氨酰胺。在给药L-谷氨酰胺十二个月之后，憩室数量减少百分之九十(90)。
Claims (10)
1.一种治疗憩室病的方法，其中，所述方法包括患有憩室病的人每天摄入0.05g/kg体重至10.0g/kg体重的L-谷氨酰胺、L-谷氨酰胺盐或L-谷氨酰胺衍生物。
2.根据权利要求1所述的方法，其中，所述摄入的化合物为L-谷氨酰胺。
3.根据权利要求2所述的方法，其中，所述L-谷氨酰胺以水溶液或悬浮液的一部分被摄入。
4.根据权利要求3所述的方法，其中，所述L-谷氨酰胺被摄入至少六个月的时期。
5.根据权利要求4所述的方法，其中，患有憩室病的人的憩室数量减少了至少百分之五十。
6.一种用于治疗憩室病的组合物，其中，所述组合物包含L-谷氨酰胺、L-谷氨酰胺盐或L-谷氨酰胺衍生物和纤维补充剂。
7.根据权利要求6所述的组合物，其中，所述组合物包含L-谷氨酰胺。
8.根据权利要求7所述的组合物，其中，所述纤维选自由甲基纤维素、小麦糊精和欧车前所组成的纤维组。
9.根据权利要求8所述的组合物，其中，所述组合物进一步包含调味剂。
10.根据权利要求所述9的组合物，其中，其为粉剂、胶囊剂、囊片剂或咀嚼片的形式。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161630831P | 2011-12-19 | 2011-12-19 | |
| US61/630,831 | 2011-12-19 | ||
| PCT/US2012/000576 WO2013095681A1 (en) | 2011-12-19 | 2012-12-14 | Methods and compositions for the treatment of diverticulosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104114165A true CN104114165A (zh) | 2014-10-22 |
| CN104114165B CN104114165B (zh) | 2016-10-19 |
Family
ID=48669319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280062802.4A Active CN104114165B (zh) | 2011-12-19 | 2012-12-14 | 用于治疗憩室病的方法和组合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9616041B2 (zh) |
| EP (2) | EP3603631B1 (zh) |
| JP (1) | JP6060176B2 (zh) |
| KR (4) | KR20180039187A (zh) |
| CN (1) | CN104114165B (zh) |
| AU (1) | AU2012355956B2 (zh) |
| BR (1) | BR112014014765A8 (zh) |
| DK (1) | DK2793875T3 (zh) |
| ES (1) | ES2770585T3 (zh) |
| IN (1) | IN2014KN01255A (zh) |
| MX (1) | MX351688B (zh) |
| RU (2) | RU2733396C2 (zh) |
| WO (1) | WO2013095681A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20200106A7 (es) | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
| EP3790545A4 (en) * | 2019-07-17 | 2021-07-28 | Emmaus Medical, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF SICKLE CLEANEMIA AND THALASSEMIA |
| US20230053227A1 (en) * | 2021-07-27 | 2023-02-16 | G&S Laboratories, Inc. | Dietary fiber compositions |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040005304A1 (en) * | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
| CN1953769A (zh) * | 2004-03-17 | 2007-04-25 | 自动健康有限公司 | 膳食添加剂及治疗消化系统相关病症的方法 |
| US20080003265A1 (en) * | 2006-06-28 | 2008-01-03 | John Francis Casey | Protein and fiber containing dietary supplement |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0738146B1 (en) * | 1994-01-11 | 2003-05-02 | N.V. Nutricia | Method of treating disorders of the animal or human body by administering amino acids |
| JP2000060487A (ja) * | 1998-08-27 | 2000-02-29 | Kao Corp | 便秘改善剤 |
| US7030092B1 (en) | 2001-08-24 | 2006-04-18 | Small Giant L.L.C. | Ultra-high fiber supplement and method of reducing weight cardiovascular risks and ingested toxins. |
| US20050058671A1 (en) * | 2003-05-09 | 2005-03-17 | Bedding Peter M.J. | Dietary supplement and method for treating digestive system-related disorders |
| US8512789B2 (en) * | 2005-11-23 | 2013-08-20 | The Coca-Cola Company | High-potency sweetener composition with dietary fiber and compositions sweetened therewith |
| CN101534656B (zh) * | 2006-11-07 | 2013-05-22 | 宝洁公司 | 包含纤维的组合物及其制备和使用方法 |
| RU2454730C1 (ru) * | 2011-03-15 | 2012-06-27 | Александр Михайлович Пузиков | Способ лечения дивертикулеза в эксперименте |
-
2012
- 2012-12-14 US US13/694,592 patent/US9616041B2/en active Active
- 2012-12-14 DK DK12860587.0T patent/DK2793875T3/da active
- 2012-12-14 RU RU2018126834A patent/RU2733396C2/ru active
- 2012-12-14 RU RU2014123433A patent/RU2662917C2/ru active
- 2012-12-14 CN CN201280062802.4A patent/CN104114165B/zh active Active
- 2012-12-14 EP EP19199336.9A patent/EP3603631B1/en active Active
- 2012-12-14 BR BR112014014765A patent/BR112014014765A8/pt not_active Application Discontinuation
- 2012-12-14 KR KR1020187009799A patent/KR20180039187A/ko not_active Application Discontinuation
- 2012-12-14 EP EP12860587.0A patent/EP2793875B1/en active Active
- 2012-12-14 WO PCT/US2012/000576 patent/WO2013095681A1/en active Application Filing
- 2012-12-14 MX MX2014007382A patent/MX351688B/es active IP Right Grant
- 2012-12-14 AU AU2012355956A patent/AU2012355956B2/en active Active
- 2012-12-14 KR KR1020177020002A patent/KR20170087531A/ko not_active Application Discontinuation
- 2012-12-14 ES ES12860587T patent/ES2770585T3/es active Active
- 2012-12-14 KR KR1020147016785A patent/KR20140103281A/ko active Application Filing
- 2012-12-14 KR KR1020177008405A patent/KR101848722B1/ko active IP Right Grant
- 2012-12-14 JP JP2014547181A patent/JP6060176B2/ja active Active
-
2014
- 2014-06-10 IN IN1255/KOLNP/2014A patent/IN2014KN01255A/en unknown
-
2017
- 2017-02-10 US US15/530,630 patent/US10258586B2/en active Active
-
2019
- 2019-02-11 US US16/501,039 patent/US11304918B2/en active Active
-
2022
- 2022-03-09 US US17/803,158 patent/US20220202758A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040005304A1 (en) * | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
| CN1953769A (zh) * | 2004-03-17 | 2007-04-25 | 自动健康有限公司 | 膳食添加剂及治疗消化系统相关病症的方法 |
| US20080003265A1 (en) * | 2006-06-28 | 2008-01-03 | John Francis Casey | Protein and fiber containing dietary supplement |
Non-Patent Citations (1)
| Title |
|---|
| 于健春: "谷氨酰胺制剂的研究进展", 《腹部外科》, vol. 13, no. 4, 31 December 2000 (2000-12-31), pages 203 - 205 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013079964A1 (en) | Combination treatment of cancer | |
| US20220202758A1 (en) | Methods and compositions for the treatment of diverticulosis | |
| US11938123B2 (en) | Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers | |
| TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
| Yao et al. | Enteral nutrition before bowel preparation improves the safety of colonoscopy in the elderly | |
| WO2022164755A1 (en) | Use of exogenous ketone esters to induce weight loss in mammals | |
| KR20200105786A (ko) | 근육 질환 예방 및 치료용 조성물 | |
| CN116911513B (zh) | 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用 | |
| CN105622562B (zh) | 一种治疗心脑血管疾病的药物组合物 | |
| TWI735658B (zh) | 用於減少代謝症候群之組合物及其應用 | |
| US20080319073A1 (en) | Colonic delivery therapeutic agents for inflammatory bowel disease | |
| JP2814892B2 (ja) | 消化管運動抑制剤 | |
| WO2012058993A1 (zh) | 安倍生坦预防或减轻缺氧导致的心功能损伤的用途 | |
| EP2537528A1 (en) | Pharmaceutical or nutritional compositions containing galactosidase, and their use | |
| EA028400B1 (ru) | Способ профилактики и лечения ожирения и избыточного веса и связанных с ними нарушений | |
| CN105919997A (zh) | 一种治疗或预防急性心衰药物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |